NEW YORK, Feb. 28, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ:INFI), in connection with its proposed merger with MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI Pharma"). Under the terms of the merger agreement, Infinity will become a wholly owned subsidiary of MEI Pharma. Pursuant to an exchange ratio set forth in the merger agreement, MEI Pharma shareholders are expected to own approximately 58.0% and Infinity shareholders are expected to only own approximately 42.0% of the outstanding equity of the combined company immediately following the merger.
Read more at prnewswire.comSHAREHOLDER ALERT: Weiss Law Investigates Infinity Pharmaceuticals, Inc.
PR Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/AI%20(artificial%20intelligence)/3D%20Graphics%20Concept%20Big%20Data%20Center%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
